← All trials
NCT04811469
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 24, 2021
- Primary completion
- Oct 30, 2021
- Completion date
- Mar 28, 2022
- First posted
- Mar 23, 2021
- Last posted
- Aug 23, 2021
- Enrollment
- 48
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Suzhou Connect BiopharmaceuticalsLead sponsor
- Nucleus Network LtdOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.